Clinical trial Recruiting at 1 site Observational Ages 18 and up

How new metabolites affect valvular heart disease

Official title: Mechanism and Effect of Novel Metabolites on Valvular Heart Disease(Hestia Study)

Run by Sun Yat-sen University · NCT07065500 · Data updated 2026-11-12

This project will test whether newly identified metabolites influence disease progression and outcomes in adults with valvular heart disease.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment4000 (estimated)
SponsorSun Yat-sen University
Academic / other
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedAugust 1, 2025
Main results expectedMarch 1, 2030
Study endsMarch 1, 2030
Registry record updatedSeptember 2, 2025
Trial IDNCT07065500 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with a clinical diagnosis of any form of valvular heart disease who can give informed consent are ideal candidates.

Probably not a fit

People without valvular heart disease, those unable to provide informed consent, or those looking for an immediate therapeutic intervention are unlikely to benefit directly.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, long-term follow-up study of adults with clinically diagnosed valvular heart disease conducted at the First Affiliated Hospital of Sun Yat-sen University. Investigators will collect clinical data and biological specimens, then perform metabolite testing on tissue samples to identify novel metabolic markers. The study aims to link metabolic signatures to risk factors, mechanisms of valve damage, and patient prognosis. Results will be used to generate hypotheses for future diagnostic biomarkers or targeted interventions.

Why it matters

Potential benefit: If successful, the study could identify metabolic markers that help predict who will worsen and point to new targets for earlier or more personalized treatment.

How similar studies have gone: Metabolomics has shown promise in other areas of cardiovascular disease, but applying detailed metabolite-mechanism studies specifically to valvular heart disease remains relatively novel and not yet well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥18 years, gender is not limited.
2. Clinical diagnosis of heart valve disease (including aortic stenosis, aortic valve closure insufficiency due to different etiologies, mitral stenosis, mitral valve closure insufficiency, pulmonic stenosis, pulmonic valve closure insufficiency, tricuspid stenosis and tricuspid closure insufficiency due to different etiologies )

Exclusion Criteria:

Patients unable to provide informed consent

Where it's running

  • The First Affiliated Hospital of Sun Yat-sen Univerity
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.